SummaryAcute myeloid leukemia (AML) manifests as phenotypically and functionally diverse cells, often within the same patient. Intratumor phenotypic and functional heterogeneity have been linked primarily by physical sorting experiments, which assume that functionally distinct subpopulations can be prospectively isolated by surface phenotypes. This assumption has proven problematic, and we therefore developed a data-driven approach. Using mass cytometry, we profiled surface and intracellular signaling proteins simultaneously in millions of healthy and leukemic cells. We developed PhenoGraph, which algorithmically defines phenotypes in high-dimensional single-cell data. PhenoGraph revealed that the surface phenotypes of leukemic blasts do no...
In this issue of Cancer Cell, de Boer et al. refine a set of acute myeloid leukemia (AML)-enriched p...
Background: A fundamental challenge for cancer therapy is that each tumor contains a highly heteroge...
abstRact Acute myeloid leukemia (AML) is characterized by a high relapse rate that has been attribut...
The precise identity of a tumour\u27s cell of origin can influence disease prognosis and outcome. Me...
Patients suffering from acute myeloid leukemia (AML) show highly heterogeneous clinical outcomes. Ne...
The recent WHO classification for acute myeloid leukemias (AML) separates entities by recurrent cyto...
Intra-tumor heterogeneity caused by clonal evolution is a major problem in cancer treatment. To addr...
Acute myeloid leukemia (AML) is a disease caused by an accumulation of immature myeloid cells, also ...
Because protein function regulates the phenotypic characteristics of cancer, a functional proteomic ...
Acute myeloid leukemia (AML) and myeloid neoplasms develop through acquisition of somatic mutations ...
Acute myeloid leukemia (AML) often presents as an oligoclonal disease whereby multiple genetically d...
<p>(A) A timeline of AML induction shows blood and bone marrow collection goals for phenotypic compa...
“Big omics data” provoke the challenge of extracting meaningful information with clinical benefit. H...
Acute Myeloid Leukemia (AML) blast cells are immature committed myeloid cells unable to spontaneousl...
Acute myeloid leukemia (AML) is believed to arise from leukemic stem-like cells (LSC) making underst...
In this issue of Cancer Cell, de Boer et al. refine a set of acute myeloid leukemia (AML)-enriched p...
Background: A fundamental challenge for cancer therapy is that each tumor contains a highly heteroge...
abstRact Acute myeloid leukemia (AML) is characterized by a high relapse rate that has been attribut...
The precise identity of a tumour\u27s cell of origin can influence disease prognosis and outcome. Me...
Patients suffering from acute myeloid leukemia (AML) show highly heterogeneous clinical outcomes. Ne...
The recent WHO classification for acute myeloid leukemias (AML) separates entities by recurrent cyto...
Intra-tumor heterogeneity caused by clonal evolution is a major problem in cancer treatment. To addr...
Acute myeloid leukemia (AML) is a disease caused by an accumulation of immature myeloid cells, also ...
Because protein function regulates the phenotypic characteristics of cancer, a functional proteomic ...
Acute myeloid leukemia (AML) and myeloid neoplasms develop through acquisition of somatic mutations ...
Acute myeloid leukemia (AML) often presents as an oligoclonal disease whereby multiple genetically d...
<p>(A) A timeline of AML induction shows blood and bone marrow collection goals for phenotypic compa...
“Big omics data” provoke the challenge of extracting meaningful information with clinical benefit. H...
Acute Myeloid Leukemia (AML) blast cells are immature committed myeloid cells unable to spontaneousl...
Acute myeloid leukemia (AML) is believed to arise from leukemic stem-like cells (LSC) making underst...
In this issue of Cancer Cell, de Boer et al. refine a set of acute myeloid leukemia (AML)-enriched p...
Background: A fundamental challenge for cancer therapy is that each tumor contains a highly heteroge...
abstRact Acute myeloid leukemia (AML) is characterized by a high relapse rate that has been attribut...